Clinical Trial Update: Effect of Recombinant Human Granulocyte Colony- Stimulating Factor on CD11b in Septic Neonates [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluated the effect of recombinant human granulocyte colony-stimulating factor on CD11b in septic neonates; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neonatal Sepsis

Drugs mentioned

• recombinant human granulocyte colony-stimulating factor (filgrastim)

Snippet

Sponsor: Ain Shams University | Conditions: Neonatal Sepsis | Phase 4 | Status: COMPLETED